This version was published on 1 May 2010

Ann Clin Biochem 2010;47:282
doi:10.1258/acb.2010.009270
© 2010 Association for Clinical Biochemistry

Letter

Serum sarcosine is not a marker for prostate cancer


Eduard A Struys1,
Annemieke C Heijboer1,
Jeroen van Moorselaar2,
Cornelis Jakobs1 and
Marinus A Blankenstein1


1 Department of Clinical Chemistry;
2 Department of Urology, VU University Medical Center, Amsterdam, The Netherlands


Email: [email protected]


The recent finding by Sreekumar et al.1 that sarcosine might play a role in the progression of prostate cancer was warmly welcomed by professionals in the field.2 The assessment of sarosine concentration in body fluids was hypothesized to serve as a novel marker for prostate cancer and prostate cancer progression.3 Currently, the blood concentration of prostate-specific antigen (PSA), a protein produced by the prostate gland, is used as a biological marker, with the limitation that an increased concentration of PSA alone does not differentiate between benign prostate conditions and prostate cancer. Sarcosine, also known as N-methylglycine, is a small endogenous molecule present in low concentrations in blood.

Careful interpretation of the data presented (Supplementary Figure 14) by Sreekumar et al.1 already showed a substantial overlap in the urinary sarcosine concentrations between men with positive and negative biopsies for cancer, implying that assessment of urinary sarcosine alone will not have clinical relevance on an individual basis. Potentially however, serum PSA concentrations in relation to serum sarcosine concentrations might have additional diagnostic value. We retrospectively determined serum sarcosine concentrations in samples obtained from three groups of men: controls (i.e. individuals who have been assessed for vitamin B12 status [n = 15]), individuals with increased serum PSA (n = 24) and individuals with prostate cancer metastases (n = 18).

Sarcosine was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) using stable-isotope labelled [2H3]sarcosine as internal standard. The LC-MS/MS method was evaluated with respect to linearity, recovery and reproducability. The structural analogues alanine and beta-alanine were physically separated from sarcosine by the LC column allowing proper quantification.

The outcomes of the sarcosine determinations are depicted in Figure 1. Our results clearly show that the mean serum sarcosine concentration does not discriminate between the three groups of men. Moreover, on an individual basis the sarcosine concentration was uninformative with respect to increased PSA concentrations and to prostate cancer progression. Our serum sarcosine data in conjunction with the urinary sarcosine data presented by Sreekumar and colleagues1 shows that there are no major alterations in the extracellular concentrations of sarcosine, implying that the assessment of sarcosine in easily obtainable body fluids like urine and serum has limited potential in the diagnostic algorithm of prostate cancer.




View larger version (16K):
[in this window]
[in a new window]

 

Figure 1 Comparison of serum sarcosine concentrations between the three groups depicted as box plots. Statistical evaluation of the data using the non-parametric Kruskal–Wallis test indicated that there are no statistical significant differences in the sarcosine concentrations between the three groups. Outliers are shown as open circles

 



  
DECLARATIONS

Top

DECLARATIONS
References

 
Competing interests: All authors declare that there are no actual or potential conflicts of interest including any financial, personal or other relationships with other people or organizations.

Guarantor: MAB.

Contributorship: EAS wrote manuscript, researched data, contributed to discussion; ACH researched data, contributed to discussion, reviewed/edited manuscript; JVM selected patients, contributed to discussion, reviewed/edited manuscript; CJ contributed to discussion, reviewed/edited manuscript; and MAB contributed to discussion, reviewed/edited manuscript.



  
References

Top

DECLARATIONS

References

 

  1. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role of sarcosine in prostate cancer progression. Nature 2009;457:910–4[Medline]
  2. Couzin J. Metabolite in urine may point to high-risk prostate cancer. Science 2009;323:865[Medline]
  3. Kuehn BM. Promosing marker found for deadly prostate cancer. JAMA 2009;301:1008[Free Full Text]

CiteULike    Complore    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter    What’s this?









This Article

Figures Only

Full Text (PDF)


All Versions of this Article:

acb.2010.009270v1

47/3/282

   most recent


Alert me when this article is cited

Alert me if a correction is posted
Services

Email this article to a friend

Similar articles in this journal


Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Citing Articles
Citing Articles via Google Scholar
Google Scholar

Articles by Struys, E. A.

Articles by Blankenstein, M. A.
Search for Related Content
PubMed

PubMed Citation
Social Bookmarking
  

  

  

  

  

  

  

  

  

What’s this?